Shan Quah

Shan Quah

Auto-generated profile, based on publicly available information

Shan Quah

A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology, and Research (A*STAR), 8A Biomedical Grove #06-06 Immunos, Singapore 138648, Republic of Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2024 in Trends in Molecular Medicine
Verified
Journal Article
Open access
SQShan Quah
Shan Quah
Gowtham SubramanianGowtham Subramanian
Gowtham Subramanian
JTJonathan S.L. Tan
Jonathan S.L. Tan
KUKagistia Hana Utami
Kagistia Hana Utami
PSPrabha Sampath
Prabha Sampath
The genesis of human disease lies in our evolutionary past. Evolution has featured a general trend towards increased morphological complexity, partly conferred by expansion in gene regulatory capacity via microRNA (miRNA) innovation. Many human diseases are directly related to the evolved roles of these miRNAs, and miRNA-based therapies are emerging as an appealing strategy for precision medicine. We focus on three categories of human disease - cancer, inflammation-linked pathologies, and neurological disorders - which are highly prevalent and are associated with substantial disease burden worldwide. In each category we discuss the pathogenic roles of miRNAs in the context of their evolved functions, as well as current and potential advances in targeting these miRNAs for disease therapy.

11 August 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
SQShan Quah
Shan Quah
GSGopinath M. Sundaram
Gopinath M. Sundaram
Gowtham SubramanianGowtham Subramanian
Gowtham Subramanian
CVCandida Vaz
Candida Vaz
JTJonathan S.L. Tan
Jonathan S.L. Tan
PSPrabha Sampath
Prabha Sampath

14 April 2021 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
SQShan Quah
Shan Quah
Gowtham SubramanianGowtham Subramanian
Gowtham Subramanian
PSPrabha Sampath
Prabha Sampath
Atopic dermatitis (AD) is a highly prevalent chronic inflammatory skin disease that is characterized by intense pruritus, seriously affecting patients’ quality of life. Its pathophysiology, which involves both the adaptive and innate immune responses as well as skin barrier defects, is still poorly understood. We recently identified a microRNA, miR-335, as a key driver of keratinocyte differentiation and cornification, which is essential for the establishment of a healthy skin barrier. However, expression of miR-335 is lost in AD, leading to barrier defect. We further demonstrated how belinostat, a histone deacetylase inhibitor, can effectively restore miR-335 and resolve the barrier defect in a dry skin model. Here, in this commentary, we highlight the role of belinostat in the treatment of AD and discuss the need for more research into crosstalk between epigenetic and non-coding RNA-based regulation, as well as possible therapeutic strategies targeting the epigenome.